SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: BigKNY3 who wrote (6504)12/16/1998 11:43:00 PM
From: BigKNY3  Read Replies (1) | Respond to of 9523
 
Merrill Lynch today reported "Our choices for possible earnings outperformance are WLA and PFE".

-ML 4th Qt PFE EPS: $.54, a 42% increase over 1997.( First Call Consensus is $.52.

-"PFE should benefit from a strong performance from Lipitor as well, good overall product trends and wholesaler stocking numbers for Europe from Viagra. Pfizer Japan, which is about 10% of sales, should benefit from a stronger Yen."

Have PFun!

BigKNY3